A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Dengue Virus
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment
- 18
- Locations
- 2
- Primary Endpoint
- Frequency of vaccine-related adverse events (AEs), as classified by both severity and seriousness, through active and passive surveillance
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. There are four types of dengue virus, and infection with one does not offer protection against the others. This study will test whether a vaccine developed to prevent infection with dengue virus type 1 (DEN1) causes a response in people's immune system and is safe.
Detailed Description
The dengue virus causes approximately 50 million cases of dengue fever and 1.5 million cases of the more severe diseases dengue hemorrhagic fever (DHS) and dengue shock syndrome (DSS) every year. There are four subtypes of the virus, and infection with one offers no protection from infection by the others. In fact, most cases of DHS and DSS occur in people infected by more than one subtype. In areas of the world where multiple subtypes of dengue are common, vaccines must be developed against each of the subtypes of dengue virus. This study will examine the safety and immune response of an investigational vaccine for preventing infection with DEN1. Participation in this study will last about 6 weeks. Participants will be randomly assigned to be injected with either the investigational study vaccine or a placebo. Participants will have a five in six chance of receiving the vaccine. The first study visit will take place on the vaccination day, on which participants will undergo a physical examination, blood draw, and pregnancy test, and then receive the vaccine. Participants will be given a thermometer and temperature card, and be told to record their temperature three times per day for 16 days after vaccination. Participants will come to follow-up visits every other day for the 16 days after vaccination, and then 3, 4, and 6 weeks after vaccination (Days 21, 28, and 42). Assessments completed during these visits will include a questionnaire about how the participant is feeling, pregnancy test, review of temperature cards, blood draw, and physical exam. Blood drawn will be analyzed to check participants' health, determine the amount of vaccine and antibodies in the blood, test markers in white blood cells and genes, and look for proteins that are important for fighting dengue infection.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In good general health as determined by physical examination, laboratory screening, and review of medical history
- •Available for the duration of the study, including approximately 6 weeks post-vaccination
- •Female participants of childbearing potential must be willing to use effective contraception for the duration of the trial
Exclusion Criteria
- •Currently breast-feeding or pregnant
- •Exhibits evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies
- •Presence of a behavioral, cognitive, or psychiatric disease that affects the ability of the participant to understand and cooperate with the requirements of the study protocol
- •Has screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), ALT, and serum creatinine, as defined in this protocol
- •Presence of any condition that would jeopardize the safety or rights of the participant or would render the participant unable to comply with the protocol
- •Significant alcohol or drug abuse in the past 12 months which has caused medical, occupational, or family problems, as indicated by participant history
- •History of a severe allergic reaction or anaphylaxis
- •Severe asthma (emergency room visit or hospitalization within the last 6 months)
- •Presence of HIV infection, determined by screening and confirmatory assays
- •Presence of hepatitis C virus (HCV) infection, determined by screening and confirmatory assays
Outcomes
Primary Outcomes
Frequency of vaccine-related adverse events (AEs), as classified by both severity and seriousness, through active and passive surveillance
Time Frame: Measured throughout study
Immunogenicity to dengue virus subtype one (DEN1), as assessed by neutralizing antibody titers
Time Frame: Measured 4 and 6 weeks after vaccination
Secondary Outcomes
- Comparison of the infectivity rates, safety, and immunogenicity of a single dose of DEN1 vaccine to those rates of previous clinical trials(Measured at study completion)
- Frequency, quantity, and duration of viremia following vaccination(Measured every other day after vaccination for 16 days, and on Days 21, 28, and 42)
- Number of vaccinees infected with DEN1, defined as recovery of vaccine virus from the blood or serum of a participant and/or by seroconversion to DEN1(Measured at study completion)